These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36880572)

  • 41. Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Hamad Saied M; van Straalen JW; de Roock S; de Joode-Smink GCJ; Verduyn Lunel FM; Swart JF; Wulffraat NM; Jansen MHA
    Vaccine; 2023 Aug; 41(37):5477-5482. PubMed ID: 37516575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation.
    Keutler A; Lainka E; Posovszky C
    Pediatr Transplant; 2024 Feb; 28(1):e14687. PubMed ID: 38317348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
    Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
    Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
    Marin M; Fiebelkorn AP; Bi D; Coleman LA; Routh J; Curns AT; McLean HQ
    Clin Infect Dis; 2021 Oct; 73(7):e1546-e1553. PubMed ID: 32766827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serologic screening and infectious diseases consultation in renal transplant candidates for measles, mumps, rubella and varicella.
    Seckin ZI; Libertin CR; Brumble LM
    Rom J Intern Med; 2021 May; 59(2):159-165. PubMed ID: 33565307
    [No Abstract]   [Full Text] [Related]  

  • 53. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
    Gothefors L; Bergström E; Backman M
    Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
    Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
    [No Abstract]   [Full Text] [Related]  

  • 60. Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China.
    Pang H; Zhou Y; Zhao W; Jiang Q
    Int J Environ Res Public Health; 2018 Sep; 15(10):. PubMed ID: 30249033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.